Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 16 | 2026 | 416 | 2.440 |
Why?
|
| Tuberculosis | 13 | 2026 | 303 | 2.320 |
Why?
|
| Metformin | 5 | 2020 | 74 | 2.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 708 | 1.230 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 221 | 1.200 |
Why?
|
| Antitubercular Agents | 4 | 2021 | 85 | 0.760 |
Why?
|
| Host-Pathogen Interactions | 4 | 2022 | 266 | 0.660 |
Why?
|
| Drug Discovery | 1 | 2020 | 98 | 0.620 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 24 | 0.580 |
Why?
|
| NAD | 1 | 2019 | 52 | 0.580 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 679 | 0.540 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 28 | 0.540 |
Why?
|
| BCG Vaccine | 2 | 2020 | 51 | 0.520 |
Why?
|
| Inflammation | 3 | 2019 | 1162 | 0.520 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 215 | 0.520 |
Why?
|
| Protein Kinases | 1 | 2017 | 153 | 0.510 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 677 | 0.500 |
Why?
|
| Energy Metabolism | 2 | 2019 | 384 | 0.480 |
Why?
|
| T-Lymphocytes | 4 | 2023 | 1019 | 0.420 |
Why?
|
| Macrophages | 5 | 2025 | 1053 | 0.420 |
Why?
|
| Major Histocompatibility Complex | 1 | 2013 | 88 | 0.400 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 178 | 0.390 |
Why?
|
| Communicable Diseases | 1 | 2013 | 91 | 0.380 |
Why?
|
| Granuloma | 2 | 2025 | 43 | 0.320 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2021 | 116 | 0.320 |
Why?
|
| Animals | 17 | 2026 | 20961 | 0.310 |
Why?
|
| Humans | 30 | 2025 | 64251 | 0.310 |
Why?
|
| Granulocytes | 2 | 2026 | 73 | 0.280 |
Why?
|
| Bacteria | 2 | 2024 | 317 | 0.270 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2022 | 247 | 0.260 |
Why?
|
| Mice | 10 | 2026 | 11003 | 0.250 |
Why?
|
| Mycobacterium abscessus | 1 | 2025 | 4 | 0.240 |
Why?
|
| Antigens, Ly | 1 | 2026 | 44 | 0.240 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2025 | 19 | 0.240 |
Why?
|
| Interleukin-17 | 1 | 2026 | 101 | 0.230 |
Why?
|
| Antigens, CD34 | 1 | 2024 | 53 | 0.210 |
Why?
|
| Virus Latency | 1 | 2023 | 32 | 0.210 |
Why?
|
| Monocytes | 3 | 2022 | 356 | 0.210 |
Why?
|
| RNA, Messenger | 2 | 2023 | 1551 | 0.200 |
Why?
|
| Antigens | 2 | 2014 | 149 | 0.200 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 180 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2024 | 153 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2025 | 2238 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2025 | 306 | 0.180 |
Why?
|
| Antigen Presentation | 2 | 2014 | 241 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2024 | 187 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2022 | 40 | 0.180 |
Why?
|
| Collagenases | 1 | 2021 | 16 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2022 | 120 | 0.170 |
Why?
|
| Reactive Oxygen Species | 3 | 2021 | 237 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 170 | 0.170 |
Why?
|
| Time | 1 | 2021 | 30 | 0.170 |
Why?
|
| Doxycycline | 1 | 2021 | 47 | 0.170 |
Why?
|
| beta-Glucans | 1 | 2021 | 56 | 0.170 |
Why?
|
| Candida albicans | 1 | 2021 | 74 | 0.170 |
Why?
|
| Macrophages, Alveolar | 1 | 2021 | 64 | 0.170 |
Why?
|
| Sirtuin 3 | 1 | 2021 | 11 | 0.170 |
Why?
|
| Histones | 2 | 2022 | 486 | 0.170 |
Why?
|
| Tuberculosis, Ocular | 1 | 2020 | 1 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 132 | 0.170 |
Why?
|
| Guinea Pigs | 1 | 2020 | 84 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 34 | 0.170 |
Why?
|
| Data Accuracy | 1 | 2020 | 31 | 0.160 |
Why?
|
| Resistin | 1 | 2019 | 7 | 0.160 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2019 | 24 | 0.160 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 182 | 0.160 |
Why?
|
| Liver | 1 | 2024 | 868 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 214 | 0.150 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2019 | 5 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 329 | 0.150 |
Why?
|
| Autoimmunity | 1 | 2020 | 240 | 0.150 |
Why?
|
| HIV-1 | 1 | 2023 | 723 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 571 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 144 | 0.140 |
Why?
|
| Sirtuins | 1 | 2018 | 26 | 0.140 |
Why?
|
| Glycolysis | 1 | 2018 | 57 | 0.140 |
Why?
|
| Lysine | 1 | 2018 | 87 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 66 | 0.130 |
Why?
|
| Lung | 3 | 2026 | 964 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 223 | 0.130 |
Why?
|
| Algorithms | 2 | 2020 | 1028 | 0.130 |
Why?
|
| Mitochondria | 1 | 2021 | 384 | 0.130 |
Why?
|
| Phenotype | 1 | 2021 | 1222 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 291 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 497 | 0.130 |
Why?
|
| Immunity | 1 | 2017 | 107 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2022 | 783 | 0.130 |
Why?
|
| HIV Infections | 1 | 2023 | 976 | 0.120 |
Why?
|
| Polycarboxylate Cement | 1 | 2016 | 4 | 0.120 |
Why?
|
| Homeostasis | 1 | 2019 | 369 | 0.120 |
Why?
|
| Mannose | 1 | 2016 | 22 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2621 | 0.120 |
Why?
|
| Nitroreductases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 4 | 0.120 |
Why?
|
| Nanotechnology | 2 | 2014 | 135 | 0.110 |
Why?
|
| Interleukin-4 | 2 | 2012 | 146 | 0.110 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 132 | 0.110 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2014 | 7 | 0.110 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2014 | 9 | 0.110 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2014 | 5 | 0.110 |
Why?
|
| Female | 7 | 2026 | 33360 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 150 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1297 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 161 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 209 | 0.100 |
Why?
|
| Riboflavin | 1 | 2013 | 17 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 178 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 119 | 0.100 |
Why?
|
| Computational Biology | 1 | 2015 | 357 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2013 | 10 | 0.100 |
Why?
|
| Microfluidics | 1 | 2013 | 25 | 0.100 |
Why?
|
| Male | 6 | 2025 | 30305 | 0.090 |
Why?
|
| Peroxisomes | 1 | 2012 | 10 | 0.090 |
Why?
|
| Thymocytes | 1 | 2012 | 23 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 29 | 0.090 |
Why?
|
| Interferon-beta | 1 | 2011 | 80 | 0.090 |
Why?
|
| Rats, Wistar | 1 | 2011 | 187 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2011 | 103 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2026 | 3450 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1247 | 0.090 |
Why?
|
| Thymus Gland | 1 | 2012 | 237 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2011 | 263 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2011 | 173 | 0.080 |
Why?
|
| Phagocytosis | 2 | 2024 | 266 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2024 | 375 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 122 | 0.080 |
Why?
|
| Acetylation | 2 | 2022 | 123 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 901 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 319 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 775 | 0.080 |
Why?
|
| Chromatin | 2 | 2023 | 616 | 0.070 |
Why?
|
| Rats | 1 | 2011 | 2005 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 645 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 391 | 0.060 |
Why?
|
| Mycobacterium marinum | 1 | 2025 | 1 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2026 | 78 | 0.060 |
Why?
|
| United States | 1 | 2019 | 7923 | 0.060 |
Why?
|
| Candida | 1 | 2025 | 41 | 0.060 |
Why?
|
| Aspergillus fumigatus | 1 | 2025 | 54 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2026 | 2140 | 0.060 |
Why?
|
| Virulence | 1 | 2025 | 195 | 0.060 |
Why?
|
| Oceania | 1 | 2025 | 2 | 0.060 |
Why?
|
| Global Burden of Disease | 1 | 2025 | 13 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 27 | 0.060 |
Why?
|
| Mycobacterium smegmatis | 1 | 2025 | 71 | 0.060 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2024 | 9 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2024 | 73 | 0.050 |
Why?
|
| Adult | 4 | 2025 | 17121 | 0.050 |
Why?
|
| Streptozocin | 1 | 2023 | 22 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2026 | 576 | 0.050 |
Why?
|
| Glycerol | 1 | 2023 | 33 | 0.050 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2025 | 91 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2024 | 517 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2024 | 526 | 0.050 |
Why?
|
| Homoserine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2024 | 285 | 0.050 |
Why?
|
| Zebrafish | 1 | 2025 | 350 | 0.050 |
Why?
|
| South Africa | 1 | 2022 | 14 | 0.050 |
Why?
|
| Singapore | 1 | 2022 | 14 | 0.050 |
Why?
|
| Autophagy | 1 | 2024 | 231 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2022 | 23 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 323 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 80 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2022 | 73 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2024 | 3070 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2023 | 233 | 0.040 |
Why?
|
| Microorganisms, Genetically-Modified | 1 | 2021 | 3 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2022 | 77 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 197 | 0.040 |
Why?
|
| CD11 Antigens | 1 | 2021 | 16 | 0.040 |
Why?
|
| Heme | 1 | 2021 | 29 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 93 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 165 | 0.040 |
Why?
|
| Serogroup | 1 | 2021 | 35 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 179 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 356 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 134 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 1383 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2021 | 52 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 37 | 0.040 |
Why?
|
| Cell Wall | 1 | 2021 | 120 | 0.040 |
Why?
|
| Dengue | 1 | 2021 | 96 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 1407 | 0.040 |
Why?
|
| Melanoma | 1 | 2024 | 331 | 0.040 |
Why?
|
| Dengue Virus | 1 | 2021 | 99 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2021 | 223 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 180 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2021 | 166 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2023 | 883 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 744 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cell Line | 1 | 2023 | 2055 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 80 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 761 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2021 | 351 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 75 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 378 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 182 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 93 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 4780 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 245 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 176 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2019 | 319 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 210 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1272 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2019 | 294 | 0.030 |
Why?
|
| Adipocytes | 1 | 2019 | 269 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2023 | 1621 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2019 | 296 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 685 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2022 | 1365 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1431 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hemolysis | 1 | 2016 | 40 | 0.030 |
Why?
|
| Polymerization | 1 | 2016 | 36 | 0.030 |
Why?
|
| Cations | 1 | 2016 | 64 | 0.030 |
Why?
|
| Middle Aged | 2 | 2025 | 17906 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2019 | 409 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2604 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 684 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2176 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1618 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 90 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1001 | 0.030 |
Why?
|
| Estrogens | 1 | 2015 | 116 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 95 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 191 | 0.030 |
Why?
|
| Microtechnology | 1 | 2014 | 6 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 260 | 0.030 |
Why?
|
| Mammals | 1 | 2016 | 219 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2014 | 34 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 99 | 0.030 |
Why?
|
| Polymers | 1 | 2016 | 327 | 0.020 |
Why?
|
| Phosphatidylethanolamines | 1 | 2012 | 19 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2012 | 29 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2012 | 26 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 109 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 512 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2012 | 89 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1494 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2013 | 128 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 348 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 14657 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 2629 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1211 | 0.020 |
Why?
|